Identification of CYP isozymes involved in benzbromarone metabolism in human liver microsomes

被引:28
作者
Kobayashi, Kaoru [1 ]
Kajiwara, Eri
Ishikawa, Masayuki
Oka, Hidenobu [2 ]
Chiba, Kan
机构
[1] Chiba Univ, Grad Sch Pharmaceut Sci, Lab Pharmacol & Toxicol, Chuo Ku, Chiba 2608675, Japan
[2] Torii Pharmaceut Co Ltd, Res Lab, Chiba, Japan
关键词
benzbromarone; human; liver microsomes; metabolism; P450; INHIBITORS; MARKET;
D O I
10.1002/bdd.1813
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Benzbromarone (BBR) is metabolized to 1'-hydroxy BBR and 6-hydroxy BBR in the liver. 6-Hydroxy BBR is further metabolized to 5,6-dihydroxy BBR. The aim of this study was to identify the CYP isozymes involved in the metabolism of BBR to 1'-hydroxy BBR and 6-hydroxy BBR and in the metabolism of 6-hydroxy BBR to 5,6-dihydroxy BBR in human liver microsomes. Among 11 recombinant P450 isozymes examined, CYP3A4 showed the highest formation rate of 1'-hydroxy BBR. The formation rate of 1'-hydroxy BBR significantly correlated with testosterone 6 beta-hydroxylation activity in a panel of 12 human liver microsomes. The formation of 1'-hydroxy BBR was completely inhibited by ketoconazole in pooled human liver microsomes. On the other hand, the highest formation rate of 6-hydroxy BBR was found in recombinant CYP2C9. The highest correlation was observed between the formation rate of 6-hydroxy BBR and diclofenac 4'-hydroxylation activity in 12 human liver microsomes. The formation of 6-hydroxy BBR was inhibited by tienilic acid in pooled human liver microsomes. The formation of 5,6-dihydroxy BBR from 6-hydroxy BBR was catalysed by recombinant CYP2C9 and CYP1A2. The formation rate of 5,6-dihydroxy BBR was significantly correlated with diclofenac 4'-hydroxylation activity and phenacetin O-deethylation activity in 12 human liver microsomes. The formation of 5,6-dihydroxy BBR was inhibited with either tienilic acid or a-naphthoflavone in human liver microsomes. These results suggest that (i) the formation of 1'-hydroxy BBR and 6-hydroxy BBR is mainly catalysed by CYP3A4 and CYP2C9, respectively, and (ii) the formation of 5,6-dihydroxy BBR is catalysed by CYP2C9 and CYP1A2 in human liver microsomes. Copyright (c) 2012 John Wiley & Sons, Ltd.
引用
收藏
页码:466 / 473
页数:8
相关论文
共 17 条
[1]  
[Anonymous], 1983, BIOCHEM J, V213, P561
[2]   Fulminant hepatic failure associated with benzbromarone treatment: A case report [J].
Arai, M ;
Yokosuka, O ;
Fujiwara, K ;
Kojima, H ;
Kanda, T ;
Hirasawa, H ;
Saisho, H .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 17 (05) :625-626
[3]   METABOLISM OF BENZBROMARONE IN MAN [J].
BROEKHUYSEN, J ;
VANHEE, M ;
SION, R ;
PACCO, M ;
DEMEULENAERE, L .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1972, 4 (02) :125-+
[4]   THE ISOLATION, IDENTIFICATION AND STRUCTURE OF A NEW HYDROXYLATED METABOLITE OF BENZBROMARONE IN MAN [J].
DEVRIES, JX ;
WALTERSACK, I ;
ITTENSOHN, A ;
WEBER, E .
XENOBIOTICA, 1989, 19 (12) :1461-1470
[5]   CYP2C9-Mediated Metabolic Activation of Losartan Detected by a Highly Sensitive Cell-Based Screening Assay [J].
Iwamura, Atsushi ;
Fukami, Tatsuki ;
Hosomi, Hiroko ;
Nakajima, Miki ;
Yokoi, Tsuyoshi .
DRUG METABOLISM AND DISPOSITION, 2011, 39 (05) :838-846
[6]  
Jansen TLTA, 2004, CLIN EXP RHEUMATOL, V22, P651
[7]   Mechanisms of benzarone and benzbromarone-induced hepatic toxicity [J].
Kaufmann, P ;
Török, M ;
Hänni, A ;
Roberts, P ;
Gasser, R ;
Krähenbühl, S .
HEPATOLOGY, 2005, 41 (04) :925-935
[8]   A benefit-risk assessment of benzbromarone in the treatment of gout - Was its withdrawal from the market in the best interest of patients? [J].
Lee, Ming-Han H. ;
Graham, Garry G. ;
Williams, Kenneth M. ;
Day, Richard O. .
DRUG SAFETY, 2008, 31 (08) :643-665
[9]   A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity [J].
Li, AP .
CHEMICO-BIOLOGICAL INTERACTIONS, 2002, 142 (1-2) :7-23
[10]   THIOPHENE DERIVATIVES AS NEW MECHANISM-BASED INHIBITORS OF CYTOCHROME-P-450 - INACTIVATION OF YEAST-EXPRESSED HUMAN LIVER CYTOCHROME-P-450-2C9 BY TIENILIC ACID [J].
LOPEZGARCIA, MP ;
DANSETTE, PM ;
MANSUY, D .
BIOCHEMISTRY, 1994, 33 (01) :166-175